Sangamo Therapeutics (SGMOQ) EPS (Basic) (2010 - 2025)

Sangamo Therapeutics' EPS (Basic) history runs 16 years deep, the most recent figure standing at -$0.13 for Q4 2025.

• On a quarterly basis, EPS (Basic) fell 15.13% year-over-year to -$0.13 in Q4 2025; TTM through Dec 2025 was -$0.44, a 10.82% increase from a year earlier, with the FY2025 full-year figure at -$0.44, up 9.65% from the prior year.
• EPS (Basic) eased to -$0.13 in Q4 2025 per SGMOQ's latest filing, from -$0.11 in the prior quarter.
• Across five years, EPS (Basic) topped out at $0.13 in Q1 2023 and bottomed at -$0.66 in Q2 2023.
• The 5-year median for EPS (Basic) is -$0.28 (2022), against an average of -$0.25.
• Across the five-year window, EPS (Basic) tumbled 2968.83% in 2021 and surged 141.69% in 2023, its largest moves.
• Year by year, EPS (Basic) stood at -$0.26 in 2021, then retreated by 29.75% to -$0.34 in 2022, then dropped by 2.7% to -$0.35 in 2023, then jumped by 66.44% to -$0.12 in 2024, then decreased by 15.13% to -$0.13 in 2025.
• Per Business Quant, the three latest SGMOQ EPS (Basic) figures stand at -$0.13 (Q4 2025), -$0.11 (Q3 2025), and -$0.08 (Q2 2025).